Lei Liu, PhD | School of Basic Medicine, Capital Medical University;
Competition Sponsor: Chinese Academy of Medical Sciences
Awardee Year: 2024
AnCel-11 represents a significant therapeutic advancement in addressing the decline of brain glucose metabolism, a critical factor in brain aging and a hallmark of neurodegenerative diseases such as Alzheimer’s disease (AD). Existing therapies to activate glycolysis are inadequate, with terazosin—a Pgk1 activator—limited by insufficient glycolytic enhancement, alpha1-adrenergic receptor-related side effects, and inhibitory effects on Pgk1 at high doses. These shortcomings restrict its clinical utility.